Acute toxicities and cumulative dose to the brain of repeated sessions of stereotactic radiotherapy (SRT) for brain metastases: a retrospective study of 184 patients.
Acute toxicity
Brain metastases
Repeated radiosurgery
Salvage radiation
Side effect
Stereotactic radiosurgery
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
10 Jan 2023
10 Jan 2023
Historique:
received:
02
03
2022
accepted:
28
12
2022
entrez:
10
1
2023
pubmed:
11
1
2023
medline:
13
1
2023
Statut:
epublish
Résumé
Stereotactic radiation therapy (SRT) is a focal treatment for brain metastases (BMs); thus, 20 to 40% of patients will require salvage treatment after an initial SRT session, either because of local or distant failure. SRT is not exempt from acute toxicity, and the acute toxicities of repeated SRT are not well known. The objective of this study was to analyze the acute toxicities of repeated courses of SRT and to determine whether repeated SRT could lead to cumulative brain doses equivalent to those of whole-brain radiotherapy (WBRT). Between 2010 and 2020, data from 184 patients treated for 915 BMs via two to six SRT sessions for local or distant BM recurrence without previous or intercurrent WBRT were retrospectively reviewed. Patients were seen via consultations during SRT, and the delivered dose, the use of corticosteroid therapy and neurological symptoms were recorded and rated according to the CTCAEv4. The dosimetric characteristics of 79% of BMs were collected, and summation plans of 76.6% of BMs were created. 36% of patients developed acute toxicity during at least one session. No grade three or four toxicity was registered, and grade one or two cephalalgy was the most frequently reported symptom. There was no significant difference in the occurrence of acute toxicity between consecutive SRT sessions. In the multivariate analysis, acute toxicity was associated with the use of corticosteroid therapy before irradiation (OR = 2.6; p = 0.01), BMV grade (high vs. low grade OR = 5.17; p = 0.02), and number of SRT sessions (3 SRT vs. 2 SRT: OR = 2.64; p = 0.01). The median volume equivalent to the WBRT dose (V Repeated SRT for local or distant recurrent BM is well tolerated, without grade three or four toxicity, and does not cause more acute neurological toxicity with repeated SRT sessions. Moreover, even for patients treated for more than ten BMs, the V
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic radiation therapy (SRT) is a focal treatment for brain metastases (BMs); thus, 20 to 40% of patients will require salvage treatment after an initial SRT session, either because of local or distant failure. SRT is not exempt from acute toxicity, and the acute toxicities of repeated SRT are not well known. The objective of this study was to analyze the acute toxicities of repeated courses of SRT and to determine whether repeated SRT could lead to cumulative brain doses equivalent to those of whole-brain radiotherapy (WBRT).
MATERIAL AND METHODS
METHODS
Between 2010 and 2020, data from 184 patients treated for 915 BMs via two to six SRT sessions for local or distant BM recurrence without previous or intercurrent WBRT were retrospectively reviewed. Patients were seen via consultations during SRT, and the delivered dose, the use of corticosteroid therapy and neurological symptoms were recorded and rated according to the CTCAEv4. The dosimetric characteristics of 79% of BMs were collected, and summation plans of 76.6% of BMs were created.
RESULTS
RESULTS
36% of patients developed acute toxicity during at least one session. No grade three or four toxicity was registered, and grade one or two cephalalgy was the most frequently reported symptom. There was no significant difference in the occurrence of acute toxicity between consecutive SRT sessions. In the multivariate analysis, acute toxicity was associated with the use of corticosteroid therapy before irradiation (OR = 2.6; p = 0.01), BMV grade (high vs. low grade OR = 5.17; p = 0.02), and number of SRT sessions (3 SRT vs. 2 SRT: OR = 2.64; p = 0.01). The median volume equivalent to the WBRT dose (V
CONCLUSION
CONCLUSIONS
Repeated SRT for local or distant recurrent BM is well tolerated, without grade three or four toxicity, and does not cause more acute neurological toxicity with repeated SRT sessions. Moreover, even for patients treated for more than ten BMs, the V
Identifiants
pubmed: 36627646
doi: 10.1186/s13014-022-02194-0
pii: 10.1186/s13014-022-02194-0
pmc: PMC9830690
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Informations de copyright
© 2023. The Author(s).
Références
Cancer Med. 2018 Jun;7(6):2350-2359
pubmed: 29745035
Clin Oncol (R Coll Radiol). 2021 May;33(5):314-321
pubmed: 33531195
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):291-8
pubmed: 10802351
J Neurooncol. 2010 Jan;96(1):103-14
pubmed: 19957014
J Neurosurg. 2016 Dec;125(Suppl 1):18-25
pubmed: 27903191
J Neurosurg. 2014 Dec;121 Suppl:60-8
pubmed: 25434938
J Neurooncol. 2016 Jan;126(1):91-97
pubmed: 26369769
Ann Oncol. 2021 Feb;32(2):171-182
pubmed: 33246022
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):870-8
pubmed: 26530756
J Neurooncol. 2013 Oct;115(1):37-43
pubmed: 23813230
J Neurosurg. 2020 Jul 10;134(6):1791-1799
pubmed: 32650308
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):996-1001
pubmed: 19783374
Crit Rev Oncol Hematol. 2020 Sep;153:103028
pubmed: 32622322
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):103-11
pubmed: 25182751
Oncoscience. 2020 Apr 24;7(3-4):19-20
pubmed: 32426417
Stereotact Funct Neurosurg. 2017;95(4):268-278
pubmed: 28810243
Front Oncol. 2017 Nov 23;7:279
pubmed: 29218301
Bull Cancer. 2013 Jan 1;100(1):15-22
pubmed: 23303795
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):31-40
pubmed: 28816158
Strahlenther Onkol. 2021 Jul;197(7):592-600
pubmed: 33725135
Neurooncol Pract. 2019 Jul;6(4):297-304
pubmed: 31386046
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):312-21
pubmed: 26678660
Lancet Oncol. 2014 Apr;15(4):387-95
pubmed: 24621620
Front Oncol. 2018 Nov 22;8:551
pubmed: 30524969
J Neurooncol. 2014 Apr;117(2):295-301
pubmed: 24488446
Strahlenther Onkol. 2022 Jun;198(6):527-536
pubmed: 35294567
Rev Esp Med Nucl Imagen Mol. 2016 Sep-Oct;35(5):332-5
pubmed: 27117985
J Neurooncol. 2016 Jan;126(2):289-98
pubmed: 26468138
Lancet Oncol. 2017 Aug;18(8):1049-1060
pubmed: 28687377
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Support Care Cancer. 2021 Nov;29(11):7073-7084
pubmed: 34080055
Cancer Radiother. 2018 Oct;22(6-7):660-681
pubmed: 30195982
Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60
pubmed: 22003987
Neurosurgery. 2021 Apr 15;88(5):E396-E405
pubmed: 33575811
J Nucl Med. 2006 Jun;47(6):904-11
pubmed: 16741298
J Radiat Res. 2013 Jul 1;54(4):727-35
pubmed: 23404206
Cancer Radiother. 2021 Jun;25(4):390-399
pubmed: 33431294
Adv Radiat Oncol. 2017 Jun 06;2(3):391-397
pubmed: 29114607
Cancer Radiother. 2021 Dec;25(8):763-770
pubmed: 34083125
Neuro Oncol. 2021 Jun 1;23(6):1024-1034
pubmed: 33095884
Cancer Radiother. 2019 Oct;23(6-7):708-715
pubmed: 31477442
Neurooncol Adv. 2021 Feb 01;3(1):vdab021
pubmed: 33738451
J Neurooncol. 2016 Apr;127(2):303-11
pubmed: 26721241
Neurosurgery. 2019 Mar 1;84(3):E189-E191
pubmed: 30629207
PLoS One. 2018 Jun 6;13(6):e0198692
pubmed: 29874299
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):993-999
pubmed: 26194677
Prog Neurol Surg. 2019;34:100-109
pubmed: 31096242
Cancer Radiother. 2016 Sep;20 Suppl:S36-60
pubmed: 27516050
Front Oncol. 2020 Nov 24;10:591884
pubmed: 33330076